<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>STAVUDINE - stavudine capsule </strong><br>KAISER FOUNDATION HOSPITALS<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>Rx only</h1>
<p class="First"><span class="Bold">(Patient Information Leaflet Included)</span></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1>WARNING </h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING STAVUDINE AND OTHER ANTIRETROVIRALS. FATAL <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> HAS BEEN REPORTED IN PREGNANT WOMEN WHO RECEIVED THE COMBINATION OF STAVUDINE AND DIDANOSINE WITH OTHER ANTIRETROVIRAL AGENTS. THE COMBINATION OF STAVUDINE AND DIDANOSINE SHOULD BE USED WITH CAUTION DURING PREGNANCY AND IS RECOMMENDED ONLY IF THE POTENTIAL BENEFIT CLEARLY OUTWEIGHS THE POTENTIAL RISK (SEE <a href="#PRECAUTIONS_PREGNANCY">WARNINGS AND PRECAUTIONS: PREGNANCY</a>)</span></p>
<p><span class="Bold">FATAL AND NONFATAL <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">PANCREATITIS</span> HAVE OCCURRED DURING THERAPY WHEN STAVUDINE WAS PART OF A COMBINATION REGIMEN THAT INCLUDED DIDANOSINE, IN BOTH TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS, REGARDLESS OF DEGREE OF <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">IMMUNOSUPPRESSION</span> (SEE </span><a href="#WARNINGS">WARNINGS</a>)</p>
</div>
<div class="Section" data-sectionCode="48780-1">
<a name="section-2"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Stavudine (d4T), a synthetic thymidine nucleoside analogue, active against the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV). </p>
<p>Stavudine Capsules are supplied for oral administration in strengths of 15, 20, 30, and 40 mg of stavudine. Each capsule also contains inactive ingredients microcrystalline cellulose, sodium starch glycolate, lactose anhydrous, and magnesium stearate. The hard gelatin shell consists of gelatin, sodium lauryl sulfate, titanium dioxide, and iron oxides.The capsules are printed with Black ink containing black iron oxide E172 dye. </p>
<p>The chemical name for stavudine is 2',3'-didehydro-3'-deoxythymidine. Stavudine has the following structural formula:</p>
<div class="Figure"><img alt="Structural Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d397a2a-06fc-467e-b014-c19e6384c8d9&amp;name=Stavudine-01.jpg"></div>
<p>Stavudine is a white to off-white crystalline solid with the molecular formula C<span class="Sub">10</span> H<span class="Sub">12</span> N<span class="Sub">2</span> O<span class="Sub">4</span> and a molecular weight of 224.2. The solubility of stavudine at 23° C is approximately 83 mg/mL in water and 30 mg/mL in propylene glycol. The n-octanol/water partition coefficient of stavudine at 23° C is 0.144.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3"></a><p></p>
<h1> MICROBIOLOGY </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2><span class="Bold">Mechanism of Action</span></h2>
<p class="First">Stavudine, a nucleoside analogue of thymidine, is phosphorylated by cellular kinases to the active metabolite stavudine triphosphate. Stavudine triphosphate inhibits the activity of   HIV-1 reverse transcriptase (RT) by competing with the natural substrate thymidine triphosphate (K<span class="Sub">i</span>=0.0083 to 0.032 μM) and by causing DNA chain termination following its incorporation into viral DNA. Stavudine triphosphate inhibits cellular DNA polymerases β and γ and markedly reduces the synthesis of mitochondrial DNA. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2><span class="Bold">Antiviral Activity</span></h2>
<p class="First">The cell culture antiviral activity of stavudine was measured in peripheral blood mononuclear cells, monocytic cells, and lymphoblastoid cell lines. The concentration of drug necessary to inhibit HIV-1 replication by 50% (EC<span class="Sub">50</span>) ranged from 0.009 to 4 μM against laboratory and clinical isolates of HIV-1. In cell culture, stavudine exhibited additive to antagonistic activity in combination with zidovudine. Stavudine in combination with either abacavir, didanosine, tenofovir, or zalcitabine exhibited additive to synergistic anti-HIV-1 activity. Ribavirin, at the 9-45 μM concentrations tested, reduced the anti-HIV-1 activity of stavudine by 2.5- to 5-fold. The relationship between cell culture susceptibility of HIV-1 to stavudine and the inhibition of HIV-1 replication in humans has not been established. </p>
<p><span class="Bold">  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></span></h2>
<p class="First">HIV-1 isolates with reduced susceptibility to stavudine have been selected in cell culture (<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>-specific) and were also obtained from patients treated with stavudine. Phenotypic analysis of HIV-1 isolates from 61 patients receiving prolonged (6-29 months) stavudine monotherapy showed that post-therapy isolates from four patients exhibited EC<span class="Sub">50</span> values more than 4-fold (range 7- to 16-fold) higher than the average pretreatment susceptibility of baseline isolates. Of these, HIV-1 isolates from one patient contained the zidovudine-resistance-associated mutations T215Y and K219E, and isolates from another patient contained the multiple-nucleoside-resistance-associated mutation Q151M. Mutations in the RT gene of HIV-1 isolates from the other two patients were not detected. The genetic basis for stavudine susceptibility changes has not been identified.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2><span class="Bold">Cross-resistance</span></h2>
<p class="First">Cross-resistance among HIV-1 reverse transcriptase inhibitors has been observed. Several studies have demonstrated that prolonged stavudine treatment can select and/or maintain mutations associated with zidovudine resistance. HIV-1 isolates with one or more zidovudine-resistance-associated mutations (M41L, D67N, K70R, L210W, T215Y/F, K219Q/E) exhibited reduced susceptibility to stavudine in cell culture. </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="section-4.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of stavudine have been evaluated in HIV-infected adult and pediatric patients (Tables 1-3). Peak plasma concentrations (C<span class="Sub">max</span>) and area under the plasma concentration-time curve (AUC) increased in proportion to dose after both single and multiple doses ranging from 0.03 to 4 mg/kg. There was no significant accumulation of stavudine with repeated administration every 6, 8, or 12 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="Bold">Absorption</span></h2>
<p class="First">Following oral administration, stavudine is rapidly absorbed, with peak plasma concentrations occurring within 1 hour after dosing. Steady-state pharmacokinetic parameters of stavudine in HIV-infected adults are shown in Table 1.</p>
<a name="Table-1"></a><table>
<caption><span>Table 1:   Steady-State Pharmacokinetic Parameters of  Stavudine in HIV-Infected Adults</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold">Parameter</span></td>
<td class="Lrule Rrule"><span class="Bold">Stavudine 40 mg BID  Mean ± SD (n=8)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule">AUC (ng•h/mL)<span class="Sup">a</span>
</td>
<td class="Lrule Rrule" align="center">2568 ± 454</td>
</tr>
<tr class="Botrule">
<td class="Lrule">C<span class="Sub">max</span> (ng/mL)</td>
<td class="Lrule Rrule" align="center">536 ± 146</td>
</tr>
<tr class="Botrule">
<td class="Lrule">C<span class="Sub">min</span> (ng/mL)</td>
<td class="Lrule Rrule" align="center">8 ± 9</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="2">
<span class="Sup">a</span>from 0 to 24 hours<br>AUC = area under the curve over 24 hours.<br>C<span class="Sub">max</span> = maximum plasma concentration.<br>C<span class="Sub">min</span> = trough or minimum plasma concentration.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2><span class="Bold">Distribution</span></h2>
<p class="First">Binding of stavudine to serum proteins was negligible over the concentration range of 0.01 to 11.4µg/mL. Stavudine distributes equally between red blood cells and plasma. Volume of distribution is shown in Table 2.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2><span class="Bold">Metabolism</span></h2>
<p class="First">Metabolism plays a limited role in the clearance of stavudine. Unchanged stavudine was the major drug-related component circulating in plasma after an 80-mg dose of <span class="Sup">14</span>C-stavudine, while metabolites constituted minor components of the circulating radioactivity. Minor metabolites include oxidized stavudine, glucuronide conjugates of stavudine and its oxidized metabolite, and an <span class="Italics">N-</span>acetylcysteine conjugate of the ribose after glycosidic cleavage, suggesting that thymine is also a metabolite of stavudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2><span class="Bold">Elimination</span></h2>
<p class="First">Following an 80-mg dose of <span class="Sup">14</span>C-stavudine to healthy subjects, approximately 95% and 3% of the total radioactivity was recovered in urine and feces, respectively. Radioactivity due to parent drug in urine and feces was 73.7% and 62.0%, respectively. The mean terminal elimination half-life is approximately 2.3 hours following single oral doses. Mean renal clearance of the parent compound is approximately 272 mL/min, accounting for approximately 67% of the apparent oral clearance</p>
<p>In HIV-infected patients, renal elimination of unchanged drug accounts for about 40% of the overall clearance regardless of the route of administration (Table 2). The mean renal clearance was about twice the average endogenous creatinine clearance, indicating active tubular secretion in addition to glomerular filtration.</p>
<a name="Table-2"></a><table>
<caption><span>Table 2: Pharmacokinetic Parameters of Stavudine in HIV-Infected  Adults: Bioavailability, Distribution, and Clearance</span></caption>
<thead><tr class="First Last">
<td class="Lrule"><span class="Bold"> Parameter</span></td>
<td class="Lrule"><span class="Bold"> Mean ± SD</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold">   n</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule">Oral bioavailability (%)                         </td>
<td class="Lrule" align="center">86.4 ±18.2</td>
<td class="Lrule Rrule" align="center">25</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Volume of distribution (L)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">46 ± 21</td>
<td class="Lrule Rrule" align="center">44</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Total body clearance (mL/min)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">594 ± 164</td>
<td class="Lrule Rrule" align="center">44</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Apparent oral clearance (mL/min)<span class="Sup">b</span>
</td>
<td class="Lrule" align="center">560 ± 182<span class="Sup">c</span>
</td>
<td class="Lrule Rrule" align="center">113</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Renal clearance (mL/min)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">237 ± 98</td>
<td class="Lrule Rrule" align="center">39</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Elimination half-life, IV dose (h)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">1.15 ± 0.35</td>
<td class="Lrule Rrule" align="center">44</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Elimination half-life, oral dose (h)<span class="Sup">b</span>
</td>
<td class="Lrule" align="center">1.6 ± 0.23</td>
<td class="Lrule Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Urinary recovery of stavudine (% of dose)<span class="Sup">a,d</span>
</td>
<td class="Lrule" align="center">42 ± 14</td>
<td class="Lrule Rrule" align="center">39</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="3">
<span class="Sup">a </span> following 1-hour IV infusion.<br><span class="Sup">b </span> following single oral dose.<br><span class="Sup">c </span> assuming a body weight of 70 kg.<br><span class="Sup">d </span> over 12-24 hours.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2><span class="Bold">Special Populations</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6.1"></a><p></p>
<h3><span class="Bold">Pediatric</span></h3>
<p class="First">For pharmacokinetic properties of stavudine in pediatric patients see Table 3.</p>
<a name="Table-3"></a><table>
<caption><span>Table 3: Pharmacokinetic Parameters (Mean ±SD) of  Stavudine in HIV- Exposed or -Infected Pediatric Patients</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center">
<span class="Bold"> </span><br><span class="Bold">Parameter</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">Ages 5 weeks</span><br><span class="Bold"> to 15 years</span>
</td>
<td class="Lrule" align="center"><span class="Bold">n</span></td>
<td class="Lrule" align="center">
<span class="Bold">Ages 14to </span><br><span class="Bold">28 days</span>
</td>
<td class="Lrule"><span class="Bold">n</span></td>
<td class="Lrule" align="center"><span class="Bold"> Day of Birth</span></td>
<td class="Lrule Rrule"><span class="Bold">   n</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Oral bioavailability (%)</td>
<td class="Lrule" align="center">76.9 ±31.7</td>
<td class="Lrule" align="center">20</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule"> </td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule Rrule"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Volume of distribution (L/kg)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">0.73 ±0.32</td>
<td class="Lrule" align="center">21</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule"> </td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Ratio of CSF: plasma concentrations (as %)<span class="Sup">b</span>
</td>
<td class="Lrule" align="center">59 ± 35</td>
<td class="Lrule" align="center">8</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule"> </td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule Rrule"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Total body clearance (mL/min/kg)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">9.75 ±3.76</td>
<td class="Lrule" align="center">21</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule"> </td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule Rrule"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Apparent oral clearance (mL/min/kg)<span class="Sup">c</span>
</td>
<td class="Lrule" align="center">13.75 ± 4.29</td>
<td class="Lrule" align="center">20</td>
<td class="Lrule" align="center">11.52 ± 5.93</td>
<td class="Lrule">30</td>
<td class="Lrule" align="center">5.08 ± 2.80</td>
<td class="Lrule Rrule">17</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Elimination half-life,IV dose (h)<span class="Sup">a</span>
</td>
<td class="Lrule" align="center">1.11 ±0.28</td>
<td class="Lrule" align="center">21</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule"> </td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Elimination half-life,oral dose (h)<span class="Sup">c</span>
</td>
<td class="Lrule" align="center">0.96 ± 0.26</td>
<td class="Lrule" align="center">20</td>
<td class="Lrule" align="center">1.59 ± 0.29</td>
<td class="Lrule">30</td>
<td class="Lrule" align="center">5.27 ± 2.01</td>
<td class="Lrule Rrule">17</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Urinary recovery of stavudine (% of dose)<span class="Sup">c,d</span>
</td>
<td class="Lrule" align="center">34 ± 16</td>
<td class="Lrule" align="center">19</td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule"> </td>
<td class="Lrule" align="center">ND</td>
<td class="Lrule Rrule"> </td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="7">
<span class="Sup">a </span> following 1-hour IV infusion.<br><span class="Sup">b </span> at median time of 2.5 hours (range 2-3 hours) following multiple oral doses.<br><span class="Sup">c </span> following single oral dose.<br><span class="Sup">d </span> over 8 hours.<br>ND = not determined.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h3>
<p class="First">Data from two studies in adults indicated that the apparent oral clearance of stavudine decreased and the terminal elimination half-life increased as creatinine clearance decreased (see Table 4). C<span class="Sub">max</span> and T<span class="Sub">max</span> were not significantly altered by <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The mean ± SD hemodialysis clearance value of stavudine was 120 ±18 mL/min (n=12); the mean ± SD percentage of the stavudine dose recovered in the dialysate, timed to occur between 2-6 hours post-dose, was 31 ± 5%. Based on these observations, it is recommended that stavudine dosage be modified in patients with reduced creatinine clearance and in patients receiving maintenance hemodialysis (see <a href="#DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</a>).</p>
<a name="Table-4"></a><table>
<caption><span>Table 4: Mean ± SD Pharmacokinetic Parameter Values of  Stavudine<span class="Sup">a </span>in Adults with Varying Degrees of  Renal Function</span></caption>
<thead><tr class="First Last">
<td class="BotRule Lrule" align="center" colspan="4"><span class="Bold">Creatinine Clearance</span></td>
<td class="Lrule Rrule" align="center">
<span class="Bold">Hemodialysis</span><br><span class="Bold">Patients<span class="Sup"> b</span></span><br><span class="Bold">n=11</span>
</td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule"> </td>
<td class="Lrule" align="center">
<span class="Bold">&gt;50 mL/min</span><br><span class="Bold">n=10</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">26-50 mL/min</span><br><span class="Bold">  n=5</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">9-25 mL/min</span><br><span class="Bold">n=5</span>
</td>
<td class="Lrule Rrule"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Creatinine clearance (mL/min) </td>
<td class="Lrule" align="center">104 ± 28</td>
<td class="Lrule" align="center">41 ± 5</td>
<td class="Lrule" align="center">17 ± 3</td>
<td class="Lrule Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Apparent oral clearance (mL/min)</td>
<td class="Lrule" align="center">335 ± 57</td>
<td class="Lrule" align="center">191 ± 39</td>
<td class="Lrule" align="center">116 ± 25</td>
<td class="Lrule Rrule" align="center">105 ± 17</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Renal clearance (mL/min)</td>
<td class="Lrule" align="center">167 ± 65</td>
<td class="Lrule" align="center">73 ± 18</td>
<td class="Lrule" align="center">17 ± 3</td>
<td class="Lrule Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">T ½ (h)</td>
<td class="Lrule" align="center">1.7 ± 0.4</td>
<td class="Lrule" align="center">3.5 ± 2.5</td>
<td class="Lrule" align="center">4.6 ± 0.9</td>
<td class="Lrule Rrule" align="center">5.4 ± 1.4</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="5">
<span class="Sup"> </span><br><span class="Sup">a  </span> Single 40-mg oral dose.<br><span class="Sup">b  </span> Determined while patients were off dialysis.<br>T<span class="Sub">½</span> = terminal elimination half-life.<br>NA = not applicable.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h3>
<p class="First">Stavudine pharmacokinetics were not altered in five non-HIV-infected patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> secondary to cirrhosis (Child-Pugh classification B or C) following the administration of a single 40-mg dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6.4"></a><p></p>
<h3><span class="Bold">Geriatric</span></h3>
<p class="First">Stavudine pharmacokinetics have not been studied in patients &gt;65 years of age. (See <span class="Bold"><a href="#PRECAUTIONS_GERIATRIC_USE">PRECAUTIONS: Geriatric Use</a></span>.) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6.5"></a><p></p>
<h3><span class="Bold">Gender</span></h3>
<p class="First">A population pharmacokinetic analysis of data collected during a controlled clinical study in HIV-infected patients showed no clinically important differences between males (n=291) and females (n=27).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6.6"></a><p></p>
<h3><span class="Bold">Race</span></h3>
<p class="First">A population pharmacokinetic analysis of data collected during a controlled clinical study in HIV-infected patients showed no clinically important differences between races (n=233 Caucasian, 39 African-American, 41 Hispanic, 1 Asian, and 4 other).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_Special_Populations_Drug_Interactions"></a><a name="section-4.6.7"></a><p></p>
<h3><span class="Bold">Drug Interactions </span></h3>
<p class="First"><span class="Bold">(see <a href="#PRECAUTIONS_DRUG_INTERACTIONS">PRECAUTIONS: Drug Interactions</a>)</span></p>
<p><span class="Italics">Zidovudine:</span> Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore, use of zidovudine in combination with stavudine should be avoided.</p>
<p><span class="Italics">Doxorubicin: In vitro</span> data indicate that the phosphorylation of stavudine is inhibited at relevant concentrations by doxorubicin.</p>
<p><span class="Italics">Ribavirin: In vitro</span> data indicate ribavirin reduces phosphorylation of lamivudine, stavudine, and zidovudine. However, no pharmacokinetic (eg, plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (eg, loss of HIV/HCV virologic suppression) interaction was observed when ribavirin and lamivudine (n=18), stavudine (n=10), or zidovudine (n=6) were coadministered as part of a multi-drug regimen to HIV/HCV co-infected patients (see <span class="Bold"><a href="#WARNINGS">WARNINGS </a> ).</span></p>
<p>Stavudine does not inhibit the major cytochrome P450 isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4; therefore, it is unlikely that clinically significant drug interactions will occur with drugs metabolized through these pathways.</p>
<p>Because stavudine is not protein-bound, it is not expected to affect the pharmacokinetics of protein-bound drugs.</p>
<p>Tables 5 and 6 summarize the effects on AUC and C<span class="Sub">max</span>, with a 95% confidence interval (CI) when available, following coadministration of stavudine with didanosine, lamivudine, and nelfinavir. No clinically significant <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed.</p>
<a name="Table-5"></a><table>
<caption><span>Table 5 : Results of Drug Interaction Studies with Stavudine: Effects of  Coadministered Drug on Stavudine Plasma AUC and C<span class="Sub">max</span> Values</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold">Drug</span></td>
<td class="Lrule" align="center"><span class="Bold">Stavudine Dosage</span></td>
<td class="Lrule"><span class="Bold">n<span class="Sup">a</span></span></td>
<td class="Lrule" align="center"><span class="Bold">AUC of Stavudine(95% CI)</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold">C<span class="Sub">max</span> of Stavudine  (95% CI)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left">Didanosine, 100 mg q12h for 4 days</td>
<td class="Lrule" align="center">40 mg q12h for 4 days</td>
<td class="Lrule" align="left">10</td>
<td class="Lrule" align="center">↔</td>
<td class="Lrule Rrule" align="center">↑ 17%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Lamivudine, 150 mg single dose</td>
<td class="Lrule" align="center">40 mg single dose</td>
<td class="Lrule" align="left">18</td>
<td class="Lrule" align="center">↔<br>( 92.7 - 100.6%)</td>
<td class="Lrule Rrule" align="center">↑ 12%<br>( 100.3 -126.1% )</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Nelfinavir, 750 mg q8h for 56 days</td>
<td class="Lrule" align="center">30-40 mg q12h for 56 days</td>
<td class="Lrule">8</td>
<td class="Lrule" align="center">↔</td>
<td class="Lrule Rrule" align="center">↔</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="5">↑ indicates increase.<br>↔ indicates no change, or mean increase or decrease of &lt;10%.<br><span class="Sup">a </span> HIV-infected patients.</td></tr>
</tbody>
</table>
<a name="Table-6"></a><table>
<caption><span>Table 6: Results of Drug Interaction Studies with Stavudine: Effects of Stavudine on Coadministered Drug Plasma AUC and C<span class="Sub">max</span>Values</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold">Drug</span></td>
<td class="Lrule" align="center"><span class="Bold">Stavudine Dosage</span></td>
<td class="Lrule" align="center"><span class="Bold">n<span class="Sup">a</span></span></td>
<td class="Lrule" align="center"><span class="Bold">AUC of Coadministered Drug (95%CI)</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold">C<span class="Sub">max</span> of Coadministered Drug (95% CI)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">Didanosine, 100 mg q12h for 4 days</td>
<td class="Lrule" align="center">40 mg q12h for 4 days</td>
<td class="Lrule">10</td>
<td class="Lrule" align="center">↔</td>
<td class="Lrule Rrule" align="center">↔    </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Lamivudine, 150 mg single dose</td>
<td class="Lrule" align="center">40 mg single dose</td>
<td class="Lrule">18</td>
<td class="Lrule" align="center">↔ <br>( 90.5 - 107.6%)</td>
<td class="Lrule Rrule" align="center"> ↔   <br>( 87.1 - 110.6%)  </td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Nelfinavir, 750 mg q8h for 56 days</td>
<td class="Lrule" align="center">30-40 mg q12h for 56 days</td>
<td class="Lrule">8</td>
<td class="Lrule" align="center">↔</td>
<td class="Lrule Rrule" align="center">↔ </td>
</tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="5">↔ indicates no change, or mean increase or decrease of &lt;10%.<br><span class="Sup">a</span> HIV-infected patients.</td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Stavudine capsules , in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (see <a href="#CLINICAL_STUDIES">Clinical Studies</a>).</span></p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL_STUDIES"></a><a name="section-6"></a><p></p>
<h1>Clinical Studies</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">Combination Therapy</span></h2>
<p class="First"> The combination use of stavudine is based on the results of clinical studies in HIV-infected patients in double- and triple-combination regimens with other antiretroviral agents.</p>
<p> One of these studies (START 1) was a multicenter, randomized, open-label study comparing stavudine (40 mg twice daily) plus lamivudine plus indinavir to zidovudine plus lamivudine plus indinavir in 202 treatment-naive patients. Both regimens resulted in a similar magnitude of inhibition of HIV RNA levels and increases in CD4 cell counts through 48 weeks. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">Monotherapy</span></h2>
<p class="First">The efficacy of stavudine was demonstrated in a randomized, double-blind study (AI455–019, conducted 1992-1994) comparing stavudine with zidovudine in 822 patients with a spectrum of HIV-related symptoms. The outcome in terms of progression of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was similar for both drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Stavudine is contraindicated in patients with clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to stavudine or to any of the components contained in the formulation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">1.<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> / Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</span>:</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals.</span> Although relative rates of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have not been assessed in prospective well-controlled trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine. Female gender, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and prolonged nucleoside exposure may be risk factors. Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk (see <span class="Bold"><a href="#PRECAUTIONS_PREGNANCY">PRECAUTIONS: Pregnancy</a> )</span>.</p>
<p>Particular caution should be exercised when administering stavudine to any patient with known risk factors for liver disease; however, cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> have also been reported in patients with no known risk factors. Generalized <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, digestive symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>); respiratory symptoms (<span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>); or <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> (including motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, see <span class="Bold"><a href="#_3_Neurologic_Symptoms">3. <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span></a></span>) might be indicative of the development of symptomatic hyperlactatemia or <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis syndrome</span>.</p>
<p>Treatment with stavudine should be suspended in any patient who develops clinical or laboratory findings suggestive of symptomatic hyperlactatemia, <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">2.<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and Toxicity</span>:</h2>
<p class="First">The safety and efficacy of stavudine have not been established in HIV-infected patients with significant underlying liver disease. During combination antiretroviral therapy, patients with preexisting liver dysfunction, including <span class="product-label-link" type="condition" conceptid="4026125" conceptname="Chronic active hepatitis">chronic active hepatitis</span>, have an increased frequency of liver function abnormalities, including severe and potentially fatal hepatic adverse events, and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.</p>
<p>An increased risk of hepatotoxicity may occur in patients treated with stavudine in combination with didanosine and hydroxyurea compared to when stavudine is used alone. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> attributed to hepatotoxicity have occurred in patients receiving this combination. This combination should be avoided.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.1"></a><p></p>
<h3><span class="Bold">Use with Interferon and Ribavirin-Based Regimens</span></h3>
<p class="First"><span class="Italics">In vitro</span> studies have shown ribavirin can reduce the phosphorylation of pyrimidine nucleoside analogues such as stavudine. Although no evidence of a pharmacokinetic or pharmacodynamic (eg, loss of HIV/HCV virologic suppression) interaction was seen when ribavirin was coadministered with stavudine in HIV/HCV co-infected patients (see <a href="#_Special_Populations_Drug_Interactions">CLINICAL PHARMACOLOGY: Drug Interactions</a>), <span class="Bold">hepatic decompensation (some fatal) has occurred in HIV/HCV co-infected patients receiving combination antiretroviral therapy for HIV and interferon and ribavirin.</span> Patients receiving interferon with or without ribavirin and stavudine should be closely monitored for treatment-associated toxicities, especially hepatic decompensation. Discontinuation of stavudine should be considered as medically appropriate. Dose reduction or discontinuation of interferon, ribavirin, or both should also be considered if worsening clinical toxicities are observed, including hepatic decompensation (eg, Child-Pugh &gt;6) (see <span class="Bold">the complete prescribing information for interferon and ribavirin).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_3_Neurologic_Symptoms"></a><a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span></span>:</h2>
<p class="First">Motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> has been reported rarely in patients receiving combination antiretroviral therapy including stavudine. Most of these cases occurred in the setting of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. The evolution of motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> may mimic the clinical presentation of Guillain-Barré syndrome (including <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>). Symptoms may continue or worsen following discontinuation of therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span>, manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the hands or feet, has been reported in patients receiving stavudine therapy. <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> has occurred more frequently in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>, with a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, or in patients receiving other drugs that have been associated with <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, including didanosine (see <span class="Bold"><a href="#ADVERSE_REACTIONS">ADVERSE REACTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span></h2>
<p class="First">Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> have occurred during therapy when stavudine was part of a combination regimen that included didanosine, in both treatment-naive and treatment-experienced patients, regardless of degree of <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>. The combination of stavudine and didanosine and any other agents that are toxic to the pancreas should be suspended in patients with suspected <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Reinstitution of stavudine after a confirmed diagnosis of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> should be undertaken with particular caution and close patient monitoring. The new regimen should not contain didanosine .</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_Fat_Redistribution"></a><a name="section-9.1"></a><p></p>
<h2><span class="Bold">Fat Redistribution </span></h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including stavudine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP), or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-10"></a><p></p>
<h1>Information for Patients</h1>
<p class="First"><span class="Bold">(See <a href="#SPL_PATIENT_PACKAGE_INSERT">Patient Information Leaflet</a>.)</span></p>
<p>Patients should be informed of the importance of early recognition of symptoms of symptomatic hyperlactatemia or <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis syndrome</span>, which include unexplained <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients in whom these symptoms develop should seek medical attention immediately. Discontinuation of stavudine therapy may be required. </p>
<p>Patients should be informed that an important toxicity of stavudine is <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. Patients should be aware that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> is manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in hands or feet, and that these symptoms should be reported to their physicians. Patients should be counseled that <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> occurs with greatest frequency in patients who have advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span> or a history of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, and that dose modification and/or discontinuation of stavudine may be required if toxicity develops. </p>
<p>Caregivers of young children receiving stavudine therapy should be instructed regarding detection and reporting of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. </p>
<p>Patients should be informed that when stavudine is used in combination with other agents with similar toxicities, the incidence of adverse events may be higher than when stavudine is used alone. An increased risk of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, which may be fatal, may occur in patients treated with the combination of stavudine and didanosine. Patients treated with this combination should be closely monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. An increased risk of hepatotoxicity, which may be fatal, may occur in patients treated with stavudine in combination with didanosine and hydroxyurea. This combination should be avoided.</p>
<p> Patients should be informed that stavudine is not a cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, and that they may continue to acquire illnesses associated with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should be advised to remain under the care of a physician when using stavudine. They should be advised that stavudine therapy has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Patients should be informed that the long-term effects of stavudine are unknown at this time. </p>
<p>Patients should be informed that the Centers for Disease Control and Prevention (CDC) recommend that HIV-infected mothers not nurse newborn infants to reduce the risk of postnatal transmission of <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. </p>
<p>Patients should be informed that redistribution or accumulation of body fat may occur in individuals receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time. </p>
<p>Patients should be advised of the importance of adherence to any antiretroviral regimen, including those that contain stavudine. </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-11"></a><p></p>
<h1>Drug Interactions</h1>
<p class="First"><span class="Bold">(see also <a href="#CLINICAL_PHARMACOLOGY">CLINICAL PHARMACOLOGY</a>)</span></p>
<p>Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. Therefore, use of zidovudine in combination with stavudine should be avoided. </p>
<p><span class="Italics">In vitro</span> data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. The clinical significance of these <span class="Italics">in vitro</span> interactions is unknown; therefore, concomitant use of stavudine with either of these drugs should be undertaken with caution. (See <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>.) </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12"></a><p></p>
<h1>Carcinogenesis, Mutagenesis, Impairment of Fertility</h1>
<p class="First">In 2-year carcinogenicity studies in mice and rats, stavudine was noncarcinogenic at doses which produced exposures (AUC) 39 and 168 times, respectively, human exposure at the recommended clinical dose. Benign and <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> in mice and rats and malignant urinary bladder tumors in male rats occurred at levels of exposure 250 (mice) and 732 (rats) times human exposure at the recommended clinical dose. </p>
<p>Stavudine was not mutagenic in the Ames, <span class="Italics">E.coli</span> reverse mutation, or the CHO/HGPRT mammalian cell forward gene mutation assays, with and without metabolic activation. Stavudine produced positive results in the <span class="Italics">in vitro</span> human lymphocyte clastogenesis and mouse fibroblast assays, and in the <span class="Italics">in vivo</span> mouse micronucleus test. In the <span class="Italics">in vitro</span> assays, stavudine elevated the frequency of chromosome aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> (concentrations of 25 to 250 μg/mL, without metabolic activation) and increased the frequency of transformed foci in mouse fibroblast cells (concentrations of 25 to 2500 μg/mL, with and without metabolic activation). In the <span class="Italics">in vivo</span> micro-nucleus assay, stavudine was clastogenic in bone marrow cells following oral stavudine administration to mice at dosages of 600 to 2000 mg/kg/day for 3 days. </p>
<p>No evidence of impaired fertility was seen in rats with exposures (based on C<span class="Sub">max </span>) up to 216 times that observed following a clinical dosage of 1 mg/kg/day</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-13"></a><p></p>
<h1> PREGNANCY </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<h2><span class="Bold">Pregnancy Category C</span></h2>
<p class="First">Reproduction studies have been performed in rats and rabbits with exposures (based on C<span class="Sub">max</span>) up to 399 and 183 times, respectively, of that seen at a clinical dosage of 1 mg/kg/day and have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. The incidence in fetuses of a common skeletal variation, unossified or incomplete ossification of sternebra, was increased in rats at 399 times human exposure, while no effect was observed at 216 times human exposure. A slight post-implantation loss was noted at 216 times the human exposure with no effect noted at approximately 135 times the human exposure. An increase in early rat neonatal mortality (birth to 4 days of age) occurred at 399 times the human exposure, while survival of neonates was unaffected at approximately 135 times the human exposure. A study in rats showed that stavudine is transferred to the fetus through the placenta. The concentration in fetal tissue was approximately one-half the concentration in maternal plasma. Animal reproduction studies are not always predictive of human response. </p>
<p>There are no adequate and well-controlled studies of stavudine in pregnant women. Stavudine should be used during pregnancy only if the potential benefit justifies the potential risk. </p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. It is unclear if pregnancy augments the risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>/<span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> syndrome reported in nonpregnant individuals receiving nucleoside analogues (see <a href="#_1_Lactic_Acidosis/Severe_Hepatomegaly_with_Steatosis">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a>). <span class="Bold">The combination of stavudine and didanosine should be used with caution during pregnancy and is recommended only if the potential benefit clearly outweighs the potential risk.</span> Healthcare providers caring for HIV-infected pregnant women receiving stavudine should be alert for early diagnosis of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>/<span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> syndrome. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>
<span class="Bold">Antiretroviral Pregnancy Registry</span>:</h2>
<p class="First">To monitor maternal-fetal outcomes of pregnant women exposed to stavudine, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-14"></a><p></p>
<h1>Nursing Mothers</h1>
<p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV.</span> Studies in lactating rats demonstrated that stavudine is excreted in milk. Although it is not known whether stavudine is excreted in human milk, there exists the potential for adverse effects from stavudine in nursing infants. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breast-feed if they are receiving stavudine</span>.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-15"></a><p></p>
<h1>Pediatric Use </h1>
<p class="First">Use of stavudine in pediatric patients from birth through adolescence is supported by evidence from adequate and well-controlled studies of stavudine in adults with additional pharmacokinetic and safety data in pediatric patients. </p>
<p>Adverse events and laboratory abnormalities reported to occur in pediatric patients in clinical studies were generally consistent with the safety profile of stavudine in adults. These studies include ACTG 240, where 105 pediatric patients ages 3 months to 6 years received stavudine 2 mg/kg/day for a median of 6.4 months; a controlled clinical trial where 185 newborns received stavudine 2 mg/kg/day either alone or in combination with didanosine from birth through 6 weeks of age; and a clinical trial where 8 newborns received stavudine 2 mg/kg/day in combination with didanosine and nelfinavir from birth through 4 weeks of age. </p>
<p>Stavudine pharmacokinetics have been evaluated in 25 HIV-infected pediatric patients ranging in age from 5 weeks to 15 years and in weight from 2 to 43 kg after IV or oral administration of single doses and twice-daily regimens and in 30 HIV-exposed or -infected newborns ranging in age from birth to 4 weeks after oral administration of twice-daily regimens (see <a href="#Table-3">CLINICAL PHARMACOLOGY, Table 3</a>). </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-16"></a><p></p>
<h1>Geriatric Use</h1>
<p class="First">Clinical studies of stavudine did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Greater sensitivity of some older individuals to the effects of stavudine cannot be ruled out. </p>
<p>In a monotherapy Expanded Access Program for patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or peripheral neuropathic symptoms were observed in 15 of 40 (38%) elderly patients receiving 40 mg twice daily and 8 of 51 (16%) elderly patients receiving 20 mg twice daily. Of the approximately 12,000 patients enrolled in the Expanded Access Program, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> or peripheral neuropathic symptoms developed in 30% of patients receiving 40 mg twice daily and 25% of patients receiving 20 mg twice daily. Elderly patients should be closely monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. </p>
<p>Stavudine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function. Dose adjustment is recommended for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><a href="#_Dosage_Adjustment">DOSAGE AND ADMINISTRATION: Dosage Adjustment</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-17"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17.1"></a><p></p>
<h2><span class="Bold">Adults </span></h2>
<p class="First">Fatal <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> has occurred in patients treated with stavudine in combination with other antiretroviral agents. Patients with suspected <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> should immediately suspend therapy with stavudine . Permanent discontinuation of stavudine should be considered for patients with confirmed <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>.</p>
<p>Stavudine therapy has rarely been associated with motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, occurring predominantly in the setting of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. If motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> develops, stavudine should be discontinued.</p>
<p>Stavudine therapy has also been associated with <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">peripheral sensory neuropathy</span>, which can be severe, is dose related, and occurs more frequently in patients being treated with other drugs that have been associated with <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> (including didanosine), in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, or in patients who have previously experienced <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>.</p>
<p>Patients should be monitored for the development of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, which is usually manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the feet or hands. Stavudine-related <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> may resolve if therapy is withdrawn promptly. In some cases, symptoms may worsen temporarily following discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one-half the dose (see <span class="Bold"><a href="#DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</a></span>). If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span> recurs after resumption, permanent discontinuation of stavudine should be considered.</p>
<p>Selected clinical adverse events that occurred in adult patients receiving stavudine in a controlled monotherapy study (Study AI455-019) are provided in Table 7.</p>
<a name="Table-7"></a><table>
<caption><span>Table 7: Selected Clinical Adverse Events in study AI455-019<span class="Sup">a</span> (Monotherapy)</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold"> </span></td>
<td class="Lrule RRule" align="center" colspan="2"><span class="Bold">Percent (%)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center"><span class="Bold">Adverse Events</span></td>
<td class="Lrule" align="center">
<span class="Bold">Stavudine<span class="Sup">b</span></span><br><span class="Bold">( 40 mg twice daily)    </span><br><span class="Bold">(n=412)</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">Zidovudine</span><br><span class="Bold">(200 mg 3 times daily)</span><br><span class="Bold"> (n=402)</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">54</td>
<td class="Lrule Rrule" align="center">49</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">50</td>
<td class="Lrule Rrule" align="center">44</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Peripheral Neurologic <br>      Symptoms/<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Lrule" align="center">52</td>
<td class="Lrule Rrule" align="center">39</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule" align="center">40</td>
<td class="Lrule Rrule" align="center">35</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">39</td>
<td class="Lrule Rrule" align="center">44</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="3">
<span class="Sup">a </span> Any severity, regardless of relationship to study drug.<br><span class="Sup">b </span> Median duration of stavudine therapy = 79 weeks; median duration of zidovudine therapy = 53 weeks.</td></tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> was observed in 3 of the 412 adult patients who received stavudine in a controlled monotherapy study.</p>
<p>Selected clinical adverse events that occurred in antiretroviral- naive adult patients receiving stavudine from two controlled combination studies are provided in Table 8.</p>
<a name="Table-8"></a><table>
<caption><span>Table 8 : Selected Clinical Adverse Events<span class="Sup">a</span> in START 1 and START 2<span class="Sup">b   </span>studies (Combination Therapy)</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"> </td>
<td class="Lrule RRule" align="center" colspan="4"><span class="Bold">Percent (%)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">
<span class="Bold"> </span><br> </td>
<td class="Lrule" align="center" colspan="2"><span class="Bold">START 1</span></td>
<td class="Lrule Rrule" align="center" colspan="2"><span class="Bold">START 2<span class="Sup">b</span></span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="Bold">Adverse Events</span></td>
<td class="Lrule" align="center"><span class="Bold">Stavudine + lamivudine + indinavir (n=100<span class="Sup">c</span>)</span></td>
<td class="Lrule" align="center"><span class="Bold"> zidovudine + lamivudine + indinavir (n=102)</span></td>
<td class="Lrule" align="center"><span class="Bold">Stavudine + didanosine + indinavir (n=102<span class="Sup">c</span>)</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold"> zidovudine + lamivudine + indinavir (n=103)</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule" align="center">43</td>
<td class="Lrule" align="center">63</td>
<td class="Lrule" align="center">53</td>
<td class="Lrule Rrule" align="center">67</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">34</td>
<td class="Lrule" align="center">16</td>
<td class="Lrule" align="center">45</td>
<td class="Lrule Rrule" align="center">39</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">25</td>
<td class="Lrule" align="center">26</td>
<td class="Lrule" align="center">46</td>
<td class="Lrule Rrule" align="center">37</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule" align="center">18</td>
<td class="Lrule" align="center">13</td>
<td class="Lrule" align="center">30</td>
<td class="Lrule Rrule" align="center">18</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">18</td>
<td class="Lrule" align="center">33</td>
<td class="Lrule" align="center">30</td>
<td class="Lrule Rrule" align="center">35</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Peripheral <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">Neurologic Symptoms</span>/<span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td class="Lrule" align="center">8</td>
<td class="Lrule" align="center">7</td>
<td class="Lrule" align="center">21</td>
<td class="Lrule Rrule" align="center">10</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="5">
<span class="Sup">a </span> Any severity, regardless of relationship to study regimen.<br><span class="Sup">b </span> START 2 compared two triple-combination regimens in 205 treatment-naive patients. Patients received either stavudine(40 mg twice daily) plus didanosine plus indinavir or zidovudine plus lamivudine plus indinavir.<br><span class="Sup">c </span> Duration of stavudine therapy = 48 weeks.</td></tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was observed in patients treated with stavudine plus didanosine, in controlled clinical studies and in postmarketing reports. </p>
<p>Selected laboratory abnormalities reported in a controlled monotherapy study (Study AI455-019) are provided in Table 9.</p>
<a name="Table-9"></a><table>
<caption><span>Table 9: Selected Adult Laboratory Abnormalities in Study AI455-019<span class="Sup">a,b</span></span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"> </td>
<td class="Lrule RRule" align="center" colspan="2"><span class="Bold">Percent (%)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center"><span class="Bold">Parameter</span></td>
<td class="Lrule" align="center">
<span class="Bold">Stavudine                    </span><br><span class="Bold">(40 mg twice daily) (n=412)</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">Zidovudine         </span><br><span class="Bold">   (200 mg 3 times daily) (n=402)</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (&gt;5.0 x ULN)</td>
<td class="Lrule" align="center">11</td>
<td class="Lrule Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">ALT (SGPT) (&gt;5.0 x ULN)</td>
<td class="Lrule" align="center">13</td>
<td class="Lrule Rrule" align="center">11</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Amylase ( &gt;1.4 x ULN)</td>
<td class="Lrule" align="center">14</td>
<td class="Lrule Rrule" align="center">13</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">
<span class="Sup">a </span> Data presented for patients for whom laboratory evaluations were performed.</td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3">
<span class="Sup">b </span> Median duration of stavudine therapy = 79 weeks; median duration of zidovudine therapy = 53 weeks.</td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="3">ULN = upper limit of normal.</td></tr>
</tbody>
</table>
<p>Selected laboratory abnormalities reported in two controlled combination studies are  provided in Tables 10 and 11.</p>
<a name="Table-10"></a><table>
<caption><span>   Table 10:  Selected Laboratory Abnormalities in START 1 and START 2 Studies (Grades 3-4)</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold"> </span></td>
<td class="Lrule Rrule" align="center" colspan="4"><span class="Bold">Percent (%)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="left"><span class="Bold"> </span></td>
<td class="Lrule" align="center" colspan="2"><span class="Bold">START 1</span></td>
<td class="Lrule Rrule" align="center" colspan="2"><span class="Bold">START 2</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">
<span class="Bold">Parameter</span><br> </td>
<td class="Lrule" align="center">
<span class="Bold">Stavudine + lamivudine</span><span class="Bold">+ indinavir </span><br><span class="Bold">(n=100)</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">Zidovudine + lamivudine + indinavir</span><br><span class="Bold">(n=102)</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">Stavudine + didanosine <span class="Bold">+ indinavir </span></span><br><span class="Bold">(n=102)</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">zidovudine + lamivudine + indinavir </span><br><span class="Bold">(n=103)</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Bilirubin (&gt;2.6 x ULN)</td>
<td class="Lrule" align="center">7</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">16</td>
<td class="Lrule Rrule" align="center">8</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) (&gt;5 x ULN)</td>
<td class="Lrule" align="center">5</td>
<td class="Lrule" align="center">2</td>
<td class="Lrule" align="center">7</td>
<td class="Lrule Rrule" align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">ALT (SGPT) (&gt;5 x ULN)</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">2</td>
<td class="Lrule" align="center">8</td>
<td class="Lrule Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">GGT (&gt;5 x ULN)</td>
<td class="Lrule" align="center">2</td>
<td class="Lrule" align="center">2</td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Lipase (&gt;2 x ULN)</td>
<td class="Lrule" align="center">6</td>
<td class="Lrule" align="center">3</td>
<td class="Lrule" align="center">5</td>
<td class="Lrule Rrule" align="center">5</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">Amylase (&gt;2 x ULN)</td>
<td class="Lrule" align="center">4</td>
<td class="Lrule" align="center">&lt;1</td>
<td class="Lrule" align="center">8</td>
<td class="Lrule Rrule" align="center">2</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" align="left" colspan="5">ULN = upper limit of normal.</td></tr>
</tbody>
</table>
<a name="Table-11"></a><table>
<caption><span>Table 11:  Selected Laboratory Abnormalities in START 1 and START 2 Studies (All Grades)</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold"> </span></td>
<td class="Lrule RRule" align="center" colspan="4"><span class="Bold">Percent (%)</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center"> </td>
<td class="Lrule" align="center" colspan="2"><span class="Bold">START 1</span></td>
<td class="Lrule Rrule" align="center" colspan="2"><span class="Bold">START 2</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">
<span class="Bold">Parameter</span><br> <br> </td>
<td class="Lrule" align="center">
<span class="Bold">Stavudine + lamivudine </span><br><span class="Bold">+ indinavir </span><br><span class="Bold">(n=100)</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">Zidovudine + lamivudine</span><br><span class="Bold">+ indinavir</span><br><span class="Bold">(n=102)</span>
</td>
<td class="Lrule" align="center">
<span class="Bold">Stavudine + didanosine +</span><br><span class="Bold">indinavir </span><br><span class="Bold">(n=102)</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">zidovudine + lamivudine +</span><br><span class="Bold">indinavir </span><br><span class="Bold">(n=103)</span>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Total Bilirubin</td>
<td class="Lrule" align="center">65</td>
<td class="Lrule" align="center">60</td>
<td class="Lrule" align="center">68</td>
<td class="Lrule Rrule" align="center">55</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>)</td>
<td class="Lrule" align="center">42</td>
<td class="Lrule" align="center">20</td>
<td class="Lrule" align="center">53</td>
<td class="Lrule Rrule" align="center">20</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">ALT (SGPT)</td>
<td class="Lrule" align="center">40</td>
<td class="Lrule" align="center">20</td>
<td class="Lrule" align="center">50</td>
<td class="Lrule Rrule" align="center">18</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">GGT</td>
<td class="Lrule" align="center">15</td>
<td class="Lrule" align="center">8</td>
<td class="Lrule" align="center">28</td>
<td class="Lrule Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">Lipase</td>
<td class="Lrule" align="center">27</td>
<td class="Lrule" align="center">12</td>
<td class="Lrule" align="center">26</td>
<td class="Lrule Rrule" align="center">19</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">Amylase</td>
<td class="Lrule" align="center">21</td>
<td class="Lrule" align="center">19</td>
<td class="Lrule" align="center">31</td>
<td class="Lrule Rrule" align="center">17</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17.2"></a><p></p>
<h2><span class="Bold">Observed During Clinical Practice </span></h2>
<p class="First">The following events have been identified during post-approval use of stavudine. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to their seriousness, frequency of reporting, causal connection to stavudine, or a combination of these factors.</p>
<p><span class="Italics">Body as a Whole</span>- <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>/<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, and redistribution/accumulation of body fat (see <span class="Bold"><a href="#_Fat_Redistribution">PRECAUTIONS: Fat Redistribution</a></span>).</p>
<p><span class="Italics">Digestive Disorders</span>- <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.</p>
<p><span class="Italics">Exocrine Gland Disorders</span>- <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> [including fatal cases (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>)].</p>
<p><span class="Italics">Hematologic Disorders</span>- <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4248718" conceptname="Macrocytosis">macrocytosis</span>.</p>
<p><span class="Italics">Liver</span>- symptomatic hyperlactatemia/<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> and <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span> (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">Metabolic Disorders</span></span>—<span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Italics">Musculoskeletal</span>- <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p><span class="Italics">Nervous System</span> - <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, severe motor <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> (most often reported in the setting of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17.3"></a><p></p>
<h2><span class="Bold">Use with Didanosine- and Hydroxyurea-Based Regimens</span></h2>
<p class="First">When stavudine is used in combination with other agents with similar toxicities, the incidence of these toxicities may be higher than when stavudine used alone. Thus, patients treated with stavudine in combination with didanosine, with or without hydroxyurea, may be at increased risk for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and hepatotoxicity, which may be fatal, and severe <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. The combination of stavudine and hydroxyurea, with or without didanosine, should be avoided (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span> and <span class="Bold"><a href="#PRECAUTIONS">PRECAUTIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17.4"></a><p></p>
<h2><span class="Bold">Pediatric Patients</span></h2>
<p class="First">Adverse reactions and serious laboratory abnormalities in pediatric patients from birth through adolescence were similar in type and frequency to those seen in adult patients (see <span class="Bold"><a href="#_PEDIATRIC_USE">PRECAUTIONS: Pediatric Use</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-18"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Experience with adults treated with 12 to 24 times the recommended daily dosage revealed no acute toxicity. Complications of chronic overdosage include <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> and hepatic toxicity. Stavudine can be removed by hemodialysis; the mean ±SD hemodialysis clearance of stavudine is 120 ± 18 mL/min. Whether stavudine is eliminated by peritoneal dialysis has not been studied.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-19"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">The interval between doses of stavudine should be 12 hours. Stavudine may be taken with or without food.</p>
<p><span class="Bold">Adults:</span>The recommended dose based on body weight is as follows: </p>
<p>40 mg twice daily for patients ≥ 60 kg.</p>
<p>30 mg twice daily for patients &lt; 60 kg.</p>
<p><span class="Bold">Pediatrics:</span> The recommended dose for newborns from birth to 13 days old is 0.5 mg/kg/dose given every 12 hours (see <span class="Bold"><a href="#CLINICAL_PHARMACOLOGY">CLINICAL PHARMACOLOGY</a></span>). The recommended dose for pediatric patients at least 14 days old and weighing less than 30 kg is 1 mg/kg/dose, given every 12 hours. Pediatric patients weighing 30 kg or greater should receive the recommended adult dosage.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_Dosage_Adjustment"></a><a name="section-19.1"></a><p></p>
<h2><span class="Bold">Dosage Adjustment</span></h2>
<p class="First">Patients should be monitored for the development of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, which is usually manifested by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the feet or hands. These symptoms may be difficult to detect in young children (see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>). If these symptoms develop during treatment, stavudine therapy should be interrupted. Symptoms may resolve if therapy is withdrawn promptly. In some cases, symptoms may worsen temporarily following discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one-half the recommended dose: </p>
<p>20 mg twice daily for patients ≥ 60 kg.</p>
<p>15 mg twice daily for patients &lt; 60 kg.</p>
<p>If <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> recurs after resumption of stavudine, permanent discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First">Stavudine may be administered to adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> with adjustment in dose as shown in Table 12.</p>
<a name="Table-12"></a><table>
<caption><span>Table 12:           Recommended Dosage Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center">
<span class="Bold">Creatinine Clearance </span><br> </td>
<td class="Lrule RRule" align="center" colspan="2"><span class="Bold">Recommended Stavudine Dose by Patient Weight</span></td>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center"><span class="Bold">(mL/min)</span></td>
<td class="Lrule" align="center"><span class="Bold">≥60 kg</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold">&lt;60 kg</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">&gt;50</td>
<td class="Lrule" align="center">40 mg every 12 hours</td>
<td class="Lrule Rrule" align="center">30 mg every 12 hours</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">26-50</td>
<td class="Lrule" align="center">20 mg every 12 hours</td>
<td class="Lrule Rrule" align="center">15 mg every 12 hours</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">10-25</td>
<td class="Lrule" align="center">20 mg every 24 hours</td>
<td class="Lrule Rrule" align="center">15 mg every 24 hours</td>
</tr>
</tbody>
</table>
<p>Since urinary excretion is also a major route of elimination of stavudine in pediatric patients, the clearance of stavudine may be altered in children with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Although there are insufficient data to recommend a specific dose adjustment of stavudine in this patient population, a reduction in the dose and/or an increase in the interval between doses should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19.3"></a><p></p>
<h2><span class="Bold">Hemodialysis Patients</span></h2>
<p class="First">The recommended dose is 20 mg every 24 hours (&gt;60 kg) or 15 mg every 24 hours (&lt;60 kg), administered after the completion of hemodialysis and at the same time of day on non-dialysis days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-20"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Stavudine capsules are available in the following strength and configuration:</p>
<a name="Table-13"></a><table>
<caption><span>Table 13: Capsule Strength/Configuration</span></caption>
<thead><tr class="First Last">
<td class="Lrule" align="center"><span class="Bold">Product Strength</span></td>
<td class="Lrule" align="center"><span class="Bold">Capsule Shell Color</span></td>
<td class="BotRule Lrule" align="center" colspan="2">
<span class="Bold">Markings on</span><span class="Bold"> Capsule (in Black Ink)</span>
</td>
<td class="Lrule" align="center"><span class="Bold">Capsules per Unit Dose Box</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold">NDC No.</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule" align="center">40 mg</td>
<td class="Lrule" align="left">Dark Orange and Dark Orange</td>
<td class="Lrule" align="center">H</td>
<td class="Lrule" align="center">61</td>
<td class="Lrule" align="center">30</td>
<td class="Lrule Rrule" align="center">0179-0028-70</td>
</tr></tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-21"></a><p></p>
<h1> Storage:</h1>
<p class="First">Stavudine Capsules should be stored in tightly closed containers at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86°F) (see USP Controlled Room Temperature).</p>
<p><span class="Bold">Manufactured By: </span></p>
<p>Hetero Drugs Limited</p>
<p>Jeedimetla, Hyderabad-500 055, India</p>
<p><span class="Bold">Manufactured for:</span></p>
<p>Camber Pharmaceuticals, Inc</p>
<p>Piscataway, NJ 08854</p>
<p><span class="Bold">Repackaged by:</span></p>
<p>KAISER FOUNDATION HOSPITALS</p>
<p>Livermore, CA 94551</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="SPL_PATIENT_PACKAGE_INSERT"></a><a name="section-22"></a><p></p>
<h1>PATIENT INFORMATION </h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">Stavudine Capsules</span></p>
<p><span class="Bold">What is stavudine?</span></p>
<p>Stavudine is a prescription medicine used in combination with other drugs to treat adults and children who are infected with HIV (the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus), the virus that causes AIDS. Stavudine belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). By reducing the growth of HIV, stavudine helps your body maintain its supply of CD4 cells, which are important for fighting HIV and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p>Stavudine will not cure your <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. At present there is no cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. Even while taking stavudine, you may continue to have HIV-related illnesses, including <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by other disease-producing organisms. Continue to see your doctor regularly and report any medical problems that occur. </p>
<p>Stavudine does not prevent a person infected with HIV from passing the virus to other people. To protect others, you must continue to practice safe sex and take precautions to prevent others from coming in contact with your blood and other body fluids. </p>
<p>There is limited information on the long-term use of stavudine.</p>
<p><span class="Bold">Who should not take stavudine?</span></p>
<p>Do not take stavudine if you are allergic to any of its ingredients, including its active ingredient, stavudine, and the inactive ingredients. (See <span class="Bold">Inactive Ingredients</span> at the end of this leaflet.) Tell your doctor if you think you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to any of these ingredients. </p>
<p><span class="Bold">How should I take stavudine? How should I store it?</span></p>
<p>Your doctor will determine your dose (the amount in each capsule) based on your body weight, kidney and liver function, and any side effects that you may have had with other medicines. Take stavudine exactly as instructed. Try not to miss a dose, but if you do, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Stavudine may be taken with food or on an empty stomach. </p>
<p>Stavudine capsules are usually taken twice a day (every 12 hours). Store stavudine capsules in a tightly closed container at room temperature away from heat and out of the reach of children and pets. Do NOT store this medicine in a damp place such as a bathroom medicine cabinet or near the kitchen sink. </p>
<p><span class="Bold Italics">If you have a kidney problem:</span> If your kidneys are not working properly, your doctor may monitor your kidney function while you take stavudine. Also, your dosage of stavudine may be adjusted. </p>
<p><span class="Bold">What should I do if someone takes an overdosage of stavudine?</span></p>
<p>If you suspect that you or someone else has taken an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of stavudine, get medical help right away. Contact a doctor or a poison control center. </p>
<p><span class="Bold">What important information should I know about taking stavudine with other medicines?</span></p>
<ul class="Disc">
<li>Do not take zidovudine (AZT) while taking stavudine, because AZT may interfere  with the actions of stavudine. Products containing AZT include Combivir<span class="Sup">® </span>,Retrovir<span class="Sup">®</span>, and Trizivir<span class="Sup">®</span>. </li>
<li>If you are taking ribavirin or interferon, your doctor may need to monitor your therapy more closely or may consider a change in your therapy. </li>
</ul>
<p>Tell your doctor or pharmacist about any other medicine, vitamin, supplement, or herbal preparation you are taking. </p>
<p><span class="Bold">What about pregnancy and nursing (breast-feeding)?</span></p>
<ul class="Disc">
<li> It is not known if stavudine can harm a human fetus. Pregnant women have experienced serious side effects when taking stavudine (the active ingredient in stavudine) in combination with didanosine and other HIV medicines. Stavudine  should be used during pregnancy only after discussion with your doctor. <span class="Bold">Tell your doctor if you become pregnant or plan to become pregnant while taking stavudine. </span>
</li>
<li>Because studies have shown stavudine is in the breast milk of animals receiving the drug, it may be present in human breast milk. The Centers for Disease Control and  Prevention (CDC) recommends that HIV-infected mothers <span class="Bold">not</span> breast-feed to reduce the risk of passing <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> to their babies and the potential for serious adverse reactions in nursing infants. Therefore, do not nurse a baby while taking stavudine. </li>
</ul>
<p><span class="Bold">What are the possible side effects of stavudine?</span></p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span></span>, severe increase of lactic acid in the blood, <span class="Bold">severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span></span>,  including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>) of the liver, and <span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></span>, which can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported among patients taking stavudine. <span class="Bold Italics">Symptoms of lactic  <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> may include:</span>
</li></ul>
<p>                       <span class="Bold Italics">·    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or unusual or unexpected <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>;</span></p>
<p>                       <span class="Bold Italics">·    feeling very weak and tired;</span></p>
<p>                       <span class="Bold Italics">·   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>;</span></p>
<p>                       <span class="Bold Italics">·   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in arms and legs.</span></p>
<p><span class="Bold Italics">If you notice these symptoms or if your medical condition has suddenly changed, stop taking stavudine and call your doctor right away. </span><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a medical emergency that must be treated in a hospital. Women (including pregnant women), overweight patients, and those who have had lengthy treatment with nucleoside medicines are more likely to develop <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Your doctor should closely monitor your liver function if you are taking stavudine and have a history of heavy alcohol use or a liver condition. </p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span></span> is a nerve disorder of the hands and feet. If not recognized   promptly, this disorder may worsen. <span class="Bold Italics">Tell your doctor right away </span><span class="Italics">if you or a child  taking stavudine has continuing <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, burning, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the feet and/or hands.</span>A child may not recognize these symptoms or know to tell you that his or her feet or hands are numb, burning, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or painful. Ask your child's doctor  for instructions on how to find out if your child develops <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> </li></ul>
<p>Let your doctor know if you or a child taking stavudine has ever had peripheral <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, because this condition occurs more often in patients who have had it  previously. <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> is also more likely to occur in patients taking drugs that affect the nerves and in patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>, but it can occur at any disease stage. If you develop <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, your doctor may tell you to stop taking stavudine. In some cases the symptoms worsen for a short  time before getting better. Once symptoms of <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> go away completely, stavudine may be started again at a lower dose. </p>
<ul class="Disc"><li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></span> is a dangerous <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas. It may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold Italics">Tell your doctor right away if you develop <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These can be signs of <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>.</span> Let your doctor know if you have ever had <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, regularly drink alcoholic beverages, or have <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span>. <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> occurs more often in patients with these conditions. It is also more likely in people with advanced HIV disease, but can occur at any disease stage. The combination of stavudine and didanosine, may increase your risk for <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. </li></ul>
<p>People who take stavudine along with other medicines that may cause similar side effects may have a higher chance of developing these side effects than if they took stavudine alone. </p>
<p><span class="Bold">Other side effects.</span> In addition to <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the most frequent side effects observed in studies of adults taking the recommended dose of stavudine were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Other side effects may include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood disorders</span>, and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>). </p>
<p>Changes in body fat have been seen in some patients taking antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump?), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time. </p>
<p><span class="Bold">What else should I know about stavudine?</span></p>
<p><span class="Bold">Inactive Ingredients:</span></p>
<p><span class="Bold">Stavudine Capsules:</span> microcrystalline cellulose, sodium starch glycolate, lactose anhydrous, and magnesium stearate in a hard gelatin shell. The hard gelatin shell consists of gelatin, sodium lauryl sulfate, titanium dioxide, and iron oxides. </p>
<p><span class="Bold Underline">The capsules are printed with Black ink containing black iron oxide E172 dye.</span></p>
<p>This medicine was prescribed for your particular condition. Do not use stavudine for another condition or give it to others. Keep stavudine and all other medicines out of the reach of children and pets at all times. Do not keep medicine that is out of date or that you no longer need. Dispose of unused stavudine through community take-back disposal programs when available or by placing it in an unrecognizable closed container in the household trash. </p>
<p>This summary does not include everything there is to know about stavudine. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have questions or concerns, or want more information about stavudine, your physician and pharmacist have the complete prescribing information upon which this leaflet was based. You may want to read it and discuss it with your doctor or other healthcare professional. Remember, no written summary can replace careful discussion with your doctor. </p>
<p>Combivir<span class="Sup">®</span>, Retrovir<span class="Sup">®</span>, and Trizivir<span class="Sup">®</span>are registered trademarks of the GlaxoSmithKline group of companies and not the trademarks of Hetero Drugs Limited. </p>
<p><span class="Bold">Manufactured By: </span></p>
<p>Hetero Drugs Limited</p>
<p>Jeedimetla, Hyderabad-500 055, </p>
<p>India</p>
<p><span class="Bold">Manufactured for:</span></p>
<p>Camber Pharmaceuticals, Inc</p>
<p>Piscataway, NJ 08854</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1> PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><img alt="Package Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d397a2a-06fc-467e-b014-c19e6384c8d9&amp;name=Stavudine-02.jpg"> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>STAVUDINE 		
					</strong><br><span class="contentTableReg">stavudine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0179-0028(NDC:31722-0518)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>STAVUDINE</strong> (STAVUDINE) </td>
<td class="formItem">STAVUDINE</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE  (Dark Orange) , ORANGE  (Dark Orange) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE </td>
<td class="formLabel">Size</td>
<td class="formItem">1mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H;61</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0179-0028-70</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078957</td>
<td class="formItem">01/27/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>KAISER FOUNDATION HOSPITALS
							(053052619)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KAISER FOUNDATION HOSPITALS</td>
<td class="formItem"></td>
<td class="formItem">053052619</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0c80436e-c57d-4cf7-afb4-a3d70e4fb5d4</div>
<div>Set id: 6d397a2a-06fc-467e-b014-c19e6384c8d9</div>
<div>Version: 1</div>
<div>Effective Time: 20100308</div>
</div>
</div> <div class="DistributorName">KAISER FOUNDATION HOSPITALS</div></p>
</body></html>
